logo
Trump diagnosed with chronic vein condition causing leg swelling

Trump diagnosed with chronic vein condition causing leg swelling

The White House said on Thursday (Friday AEST) that US President Donald Trump is experiencing swelling in his lower legs and bruising on his right hand, after photographs emerged of Trump with swollen ankles and makeup covering the afflicted part of his hand.
White House spokeswoman Karoline Leavitt, reading a letter from Trump's doctor at a press briefing, said both ailments were benign. His leg swelling is from a 'common' vein condition, and his hand is bruised from shaking so many hands, she told reporters.
The disclosure sought to put to rest a raft of internet rumours that the 79-year-old Trump might be suffering from a serious ailment based on the photographic evidence.
After Leavitt's briefing, the White House released the letter from a U.S. Navy officer who is Trump's physician, Sean Barbabella. It said Trump underwent a suite of tests about the issues. Barbabella said an ultrasound on the president's legs 'revealed chronic venous insufficiency, a benign and common condition, particularly in individuals over the age of 70.'
The letter said there was no evidence Trump had contracted deep vein thrombosis, a malady that afflicted former President Richard Nixon, or arterial disease. Additional exams identified no signs of heart failure, kidney impairment, or a systemic illness, Barbabella said.
Leavitt told reporters Trump was not experiencing discomfort due to the condition. Barbabella also said that Trump had bruising on the back of his right hand.
He described this as 'consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen.'
'President Trump remains in excellent health,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump takes aim at ‘foreign freeloading nations' over drug prices in new threat to PBS
Trump takes aim at ‘foreign freeloading nations' over drug prices in new threat to PBS

The Age

time5 days ago

  • The Age

Trump takes aim at ‘foreign freeloading nations' over drug prices in new threat to PBS

Washington: US President Donald Trump has blamed 'foreign freeloading nations' for the high drug prices faced by Americans and told pharmaceutical firms to negotiate harder with other countries, in a new threat to programs such as Australia's Pharmaceutical Benefits Scheme. Trump issued letters to the bosses of 17 drug firms on Thursday (Friday AEST) demanding they extend 'most favoured nation' pricing to the US Medicaid scheme, and guarantee such pricing for new drugs. It means other comparable, high-income nations could not be offered cheaper prices than the US. 'Domestic MFN pricing will require you, and all manufacturers, to negotiate harder with foreign freeloading nations,' Trump wrote in the letters. 'US trade policy will endeavour to support this. However, increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers through an explicit agreement with the United States.' The letters were sent to major drugmakers including Pfizer, Eli Lilly, AstraZeneca and Johnson & Johnson, and published on Trump's social media. They did not mention Australia but referred to putting 'an end to the free ride of American innovation by European and other developed nations'. Under the PBS, Australians can buy life-saving drugs worth thousands of dollars for as little as $31.60 a script after the government negotiates with the drug company to secure a lower price based on buying in bulk. Trump's letter makes explicit instructions to drug firms to 'negotiate harder' and return those extra profits to American patients and taxpayers.

ASX set to fall, Wall Street mixed; Microsoft, Meta surge
ASX set to fall, Wall Street mixed; Microsoft, Meta surge

Sydney Morning Herald

time5 days ago

  • Sydney Morning Herald

ASX set to fall, Wall Street mixed; Microsoft, Meta surge

Stocks indexes were mixed in afternoon trading on Wall Street after a health care sector slide offset some of the gains from a rally among big tech companies. The S&P 500 was up less than 0.1 per cent, holding just below the record high it set on Monday. The Dow Jones Industrial Average fell 88 points, or 0.2 per cent. The technology-heavy Nasdaq rose 0.3 per cent and is on track for a record. The Australian sharemarket is set to retreat, with futures at 5.10am AEST pointing to a loss of 52 points, or 0.6 per cent, at the open. The ASX lost 0.2 per cent on Thursday. The Australian dollar was fetching 64.33 US cents at 5.25am. Health care stocks were the biggest drag on the market after the White House released letters asking big pharmaceutical companies to cut prices and make other changes in the next 60 days. Eli Lilly & Co. fell 2 per cent, UnitedHealth Group slid 4.9 per cent and Bristol-Myers Squibb was 4.5 per cent lower. Roughly 70 per cent of stocks in the S&P 500 were losing ground, but big technology stocks with hefty values helped temper the impact of losses in health care and other sectors. Loading Technology stocks rose following results from big companies showcasing advancements in artificial intelligence. Facebook and Instagram's parent company Meta Platforms surged 11.9 per cent after it crushed Wall Street's sales and profit targets even as the company continues to pour billions into artificial intelligence. Microsoft jumped 4.1 per cent after also posting better results than analysts expected. The software pioneer also gave investors an encouraging update on its Azure cloud computing platform, which is a centrepiece of the company's artificial intelligence efforts.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store